Analysis of all constituents of entire Reactome pathways identified by the presence of upregulated or mutated genes helped Valdivia et al. in the February, 2023 issue of Translational Vision Science & Technology to identify druggable targets and potential drugs for the treatment of diabetic retinopathy (DR). Drugs affecting MMP13 and LGALS3 in the regulation of myeloid cell differentiation by RUNX2 were notable candidates.